Cellectis S.A. · EURONEXT:ALCLS
Cellectis — Investor Presentation (November 2026)
35 slides from Cellectis's investor presentation, November 2026
Slide 1: Therapeutic Gene Surgery
Therapeutic Gene Surgery C O R P O R A T E P R E S E N T AT I O N - N O V E M B E R 2 0 2 6
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains “forward-looking” statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “design”, “expect”, “initiate”, “into”, “
Slide 3: Life, no longer defined by disease
OUR MISSION Life, no longer defined by disease 26 YEARS OF GENE EDITING
Slide 4: Cellectis at a Glance
Cellectis at a Glance STRATEGIC REFOCUS LEAD PROGRAMS OUR GENE EDITING RUNWAY INTO H2 2028 IN VIVO GENE EDITING PLATFORM ▪ A differentiated platform ▪ Realignment of the ▪ Exiting ex vivo cell therapy ▪ .HEAL-101 (APOC3) operating model targeting programs Severe hypertriglyceridemia ▪ Single-base pr
Slide 5: A New Modality on a Platform 26 Years in the Making
A New Modality on a Platform 26 Years in the Making LICENSED PARTNERS 26 YEARS OF GENE EDITING Gene editing was pioneered by Cellectis A deep understanding of editors 3 licensed programs in clinical development and DNA programming TALEN® is a registered trademark owned by Cellectis 5
Slide 6: sHTG: A Leading Cause of Acute Pancreatitis
sHTG: A Leading Cause of Acute Pancreatitis Severe hypertriglyceridemia (sHTG) TARGET POPULATION A chronic lipid metabolism disorder in which triglyceride-rich particles build up in the blood. ~1.1M Above 500 mg/dL, they can injure the pancreas high-risk population² and cause acute pancreatitis WHAT
Slide 7: sHTG: Significant Burden Despite Conventional Treatment
sHTG: Significant Burden Despite Conventional Treatment Severe hypertriglyceridemia (sHTG) ACUTE PANCREATITIS 3x 4x 65% of patients remained above target despite lipid-lowering therapy2 increased risk of higher risk of intensive pancreatitis1 care unit admission1 1. Kiss L et al. Sci Rep. 2018;8:140
Slide 8: HeFH: A Major Driver of Premature Cardiovascular Disease
HeFH: A Major Driver of Premature Cardiovascular Disease Severe hypercholesterolemia (sHC) TARGET POPULATION A chronic lipid metabolism disorder in which LDL-C builds up in the blood. Prolonged exposure drives ~2.3M HeFH adults² atherosclerosis and cardiovascular disease WHAT DEFINES THE TARGET GROU
Slide 9: HeFH: High Cardiovascular Risk, Poor LDL-C Control Despite Treatment
HeFH: High Cardiovascular Risk, Poor LDL-C Control Despite Treatment Heterozygous Familial Hypercholesterolemia (HeFH) CARDIOVASCULAR EVENTS 10-20x 86% ~97% of treated HeFH patients do not meet LDL-C goals despite lipid lowering increased risk of of reported CV events atherosclerotic in patients not
Slide 10: Two Validated Targets, Two Clear Paths to the Clinic
Two Validated Targets, Two Clear Paths to the Clinic .HEAL-101 APOC3 .HEAL-201 PCSK9 Reduced APOC3 TG Lower risk of PCSK9 LDL-C 0 cardiovascular reduction lowering pancreatitis reduction lowering 0 events Target engagement Validated registration Clinical benefit Target engagement Validated registrat
Slide 11: Our Approach: One Injection with a Potential Long-Lasting Effect
Our Approach: One Injection with a Potential Long-Lasting Effect ORAL THERAPIES Oral therapies: often not Daily pills, enough on their own long-term INJECTABLE THERAPIES Used alongside or Repeated instead of oral therapies injections .HEAL-101 Edits a single base of the APOC3 gene OUR APPROACH Poten
Slide 12: How It Works: From IV Injection to Liver Cells
How It Works: From IV Injection to Liver Cells product AAAAAA 3′ AAAAAA 3′ Product: mRNA coding for a gene editor in a lipid liver cells nanoparticle (LNP) A single IV injection for a potential long-lasting effect IV: Intravenous 12
Slide 13: One Gene Editing Platform, Multiple Editing Modalities
One Gene Editing Platform, Multiple Editing Modalities One TALE DNA-binding USED FOR domain TALEN® NUCLEASE EDITING ALLOGENEIC CAR-T TALEB BASE EDITING .HEAL-101 Protein-based DNA recognition, no guide RNA needed TALEM EPIGENETIC EDITING .HEAL-201 26 years Intellectual Property No DNA break of gene
Slide 14: .HEAL-101
.HEAL-101 G E N E S U R G E R Y For Severe Hypertriglyceridemia (sHTG)
Slide 15: .HEAL-101: A Single Base Change, No DNA Break
.HEAL-101: A Single Base Change, No DNA Break .HEAL-101 is a base editor C to T conversion It modifies one base in DNA .HEAL-101 No DNA break offering the potential of an improved safety profile 15
Slide 16: .HEAL-101: Disables APOC3 Expression
.HEAL-101: Disables APOC3 Expression APOC3 gene expression Editing location A stop codon is generated Undetectable APOC3 protein 16
Slide 17: .HEAL-101: Efficient Editing, No Detectable Off-Target Editing
.HEAL-101: Efficient Editing, No Detectable Off-Target Editing .HEAL-101 mRNA is introduced in hepatic cell lines Efficient on-site modification with No modification no DNA alteration of top putative off-sites Efficient On-Target Base Editing No Detectable Editing at Putative Off-Target Sites ~90% w
Slide 18: .HEAL-101 Stops APOC3 Expression In Vitro
.HEAL-101 Stops APOC3 Expression In Vitro Frequency of APOC3 editing Quantification of APOC3 secretion 100 1.2 APOC3 base editing (%) Normalized APOC3 80 1.0 Frequency of 0.8 secretion 60 0.6 40 0.4 20 0.2 0 0.0 0 1 2 3 4 5 6 0 1 2 3 4 5 6 LNP-mRNA units LNP-mRNA units Research data 18
Slide 19: .HEAL-101 Lowers Triglycerides in Humanized Mice
.HEAL-101 Lowers Triglycerides in Humanized Mice 100 20 20 Before/After treatment (%) Change from baseline (%) 0 0 Frequency of editing (%) 80 -20 -20 .HEAL-101 Change 60 -40 -40 40 -60 -60 20 -80 -80 0 -100 -100 Control .HEAL-101 Base editing Indels Control .HEAL 101 Precise Decrease of Drop of APO
Slide 20: .HEAL-101 Lowers Triglycerides by 76% in hAPOC3 Mice
.HEAL-101 Lowers Triglycerides by 76% in hAPOC3 Mice APOC3 Triglycerides .HEAL-101 100 100 Change from baseline (%) Change from baseline (%) 50 50 20 20 0 0 -20 -20 -40 -40 70% 76% -60 decrease -60 decrease -80 -80 -100 -100 Control .HEAL-101 Control .HEAL-101 Research data 20
Slide 21: .HEAL-201
.HEAL-201 G E N E S U R G E R Y For Severe Hypercholesterolemia (sHC)
Slide 22: .HEAL-201: Silencing PCSK9 without Touching the DNA Sequence
.HEAL-201: Silencing PCSK9 without Touching the DNA Sequence .HEAL-201 is an epigenetic modulator PCSK9 is active .HEAL-201 binds target Epigenetically modulates the PCSK9 gene without altering PCSK9 is silenced the DNA sequence No DNA sequence change 22 Research data
Slide 23: .HEAL-201 Promotes Efficient and Specific Knockdown of PCSK9
.HEAL-201 Promotes Efficient and Specific Knockdown of PCSK9 Epigenetic change in the DNA without sequence modification Efficient PCSK9 mRNA transcription reduction 1.0 0.8 Fold Change 0.6 0.4 0.2 0.0 Control .HEAL-201 PCSK9 transcription is shut down Research data 23
Slide 24: .HEAL-201 Promotes Efficient and Specific Knockdown of PCSK9
.HEAL-201 Promotes Efficient and Specific Knockdown of PCSK9 Epigenetic change in the DNA without sequence modification Efficient PCSK9 protein reduction 100 90 Normalized PCSK9 80 70 secretion (%) 60 Mock 50 40 .HEAL-201 30 20 10 0 0 7 14 21 28 35 42 49 Day # (Post-Transfection) PCSK9 protein is tu
Slide 25: .HEAL-201 Promotes Efficient and Specific Knockdown of PCSK9
.HEAL-201 Promotes Efficient and Specific Knockdown of PCSK9 Transcriptome post .HEAL-201 treatment shows a precise modification Downregulated →Upregulated PCSK9 → Significant Significantly downregulated Significantly upregulated Not Significant Other genes .HEAL-201: high specificity on PCSK9 o
Slide 26: .HEAL-201 Epigenetic Modification is Stable Over Time
.HEAL-201 Epigenetic Modification is Stable Over Time 20 .HEAL-201 treated with respect to W-1 (%) 0 Decrease of PCSK9 .HEAL-201 -20 -40 -60 -80 -100 -1 0 1 2 3 4 5 Time (week) .HEAL-201 promotes rapid and durable decrease of PCSK9 Research data 26
Slide 27: Clinical Development Plan
Clinical Development Plan For .HEAL-101 and .HEAL-201
Slide 28: .HEAL-101 Clinical Development Plan
.HEAL-101 Clinical Development Plan 1 Phase 1 Study 2 Phase 1b/2 Study Patient population: severe hypertriglyceridemia Patient population: severe high risk (sHTG) hypertriglyceridemia (sHTG) OBJECTIVES OBJECTIVES ▪ First-in-Human for safety and tolerability ▪ Expand to global populations ▪ Establish
Slide 29: .HEAL-201 Clinical Development Plan
.HEAL-201 Clinical Development Plan 1 Phase 1 Study 2 Phase 1b/2 Study Patient population: Severe Patient population: severe hypercholesterolemia, hypercholesterolemia, HeFH ≥190 mg/dL HeFH ≥190 mg/dL, high risk patients OBJECTIVES OBJECTIVES ▪ First-in-Human for safety and tolerability ▪ Severe gen
Slide 30: Advancing Toward First-In-Human Proof-of-Concept
Advancing Toward First-In-Human Proof-of-Concept Getting to first human data IND/CTA enabling activities ▪ Plan to start an IIT in China ▪ FDA / EMA preparation initiated ▪ GMP manufacturing starting ▪ Manufacturing scope broadened toward ▪ Phase 1 designed to accelerate dose global supply selection
Slide 31: Cellectis Targeted Roadmap
Cellectis Targeted Roadmap Advancing 2 Lead Assets FIH Data disclosure .HEAL-101 targeting APOC3 in severe hypertriglyceridemia H1-27 H2-27 .HEAL-201 targeting PCSK9 in severe hypercholesterolemia H2-27 H1-28 Continuing Existing Partnerships Targeting Cash Runway into H2 2028* Exiting internal cell
Slide 32: Thank You
Thank You Reach us at: investors@cellectis.com Cellectis Paris Cellectis New York Cellectis Raleigh 8, rue de la Croix Jarry 75013 430 East 29th Street 2500 Sumner Boulevard Paris – France New York, NY, 10016 – USA Raleigh, NC, 27616 – USA Cellectis®, TALEN® and our corporate logos are registered tr
Slide 33: APPENDIX
APPENDIX
Slide 34: Diversified Partnerships with Industry Leaders
Diversified Partnerships with Industry Leaders CAR-T – CD19 CAR-T – 15 targets TILs Cell and Gene Therapies cema-cel ALLO-316 (CD70) IOV-4001 Exclusive1 U.S. rights Exclusive worldwide Research collaboration Joint Research and worldwide license exclusively license to 15 allogeneic and exclusive Coll
Slide 35: Partnered Cell Therapy Pipeline
Partnered Cell Therapy Pipeline INDICATION / STUDY PRECLINICAL PHASE 1 PHASE 21 UPCOMING EXPECTED MILESTONE TYPE ALPHA3 LBCL Cema-cel (CD19) 1 (Allogeneic CAR-T) TRAVERSE2 RCC ALLO-316 (CD70) (Allogeneic CAR-T) IOV-GM1-201 Melanoma IOV-4001 (TIL) UNDISCLOSED 1. cemacabtagene ansegedleucel has been d